Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Estrella Immunopharma, Inc. (NASDAQ:ESLA) saw a significant growth in short interest in July. As of July 15th, there was short interest totalling 19,100 shares, a growth of 8.5% from the June 30th total of 17,600 shares. Based on an average daily volume of 17,600 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.2% of the shares of the stock are short sold.

Estrella Immunopharma Stock Performance

ESLA stock traded up $0.14 during mid-day trading on Thursday, reaching $1.70. 25,202 shares of the company’s stock were exchanged, compared to its average volume of 59,933. The stock’s 50 day moving average is $1.16 and its 200 day moving average is $1.13. Estrella Immunopharma has a 12-month low of $0.81 and a 12-month high of $33.00.

Estrella Immunopharma (NASDAQ:ESLA) last announced its earnings results on Tuesday, May 14th. The company reported ($0.01) EPS for the quarter.

Hedge Funds Weigh In On Estrella Immunopharma

A hedge fund recently bought a new stake in Estrella Immunopharma stock. ATW Spac Management LLC purchased a new stake in Estrella Immunopharma, Inc. (NASDAQ:ESLA) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 40,000 shares of the company’s stock, valued at approximately $44,000. ATW Spac Management LLC owned about 0.11% of Estrella Immunopharma as of its most recent filing with the Securities and Exchange Commission (SEC). 0.35% of the stock is currently owned by institutional investors and hedge funds.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.